Agile Therapeutics, Inc.
Agile Therapeutics, Inc., a pioneering biopharmaceutical company headquartered in the United States, focuses on developing innovative contraceptive solutions for women. Founded in 2007, Agile has made significant strides in the women's health sector, particularly with its flagship product, Twirla, a transdermal contraceptive patch that offers a unique, convenient alternative to traditional birth control methods. With a commitment to addressing unmet needs in reproductive health, Agile Therapeutics has positioned itself as a leader in the industry, emphasising patient-centric solutions. The company operates primarily in the US market, where it continues to expand its reach and influence. Agile's dedication to research and development, coupled with its strategic partnerships, underscores its role as a key player in advancing women's health care.
DitchCarbon Score
How does Agile Therapeutics, Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Agile Therapeutics, Inc.'s score of 23 is lower than 84% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Agile Therapeutics, Inc.'s reported carbon emissions
Agile Therapeutics, Inc., headquartered in the US, currently does not have publicly available carbon emissions data for the most recent year, nor specific reduction targets or initiatives outlined in their climate commitments. Without concrete emissions figures or defined reduction strategies, it is challenging to assess their environmental impact or progress towards sustainability goals. However, the absence of data may indicate an opportunity for Agile Therapeutics to enhance transparency and engage in climate action within the pharmaceutical industry. As the sector increasingly prioritises sustainability, establishing measurable targets and reporting emissions could align Agile Therapeutics with industry standards and stakeholder expectations.
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Agile Therapeutics, Inc. is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
